Case History: Discovery and Development of the PI3Kδ-Selective Inhibitor Joenja® (Leniolisib, CDZ173) as a Targeted Therapy for Patients with Activated PI3Kδ Syndrome (APDS)
Tools
Tools
Tools
Hoegenauer, Klemens, Soldermann, Nicolas, Burkhart, Christoph and Kalis, Christoph (2025) Case History: Discovery and Development of the PI3Kδ-Selective Inhibitor Joenja® (Leniolisib, CDZ173) as a Targeted Therapy for Patients with Activated PI3Kδ Syndrome (APDS). Medicinal Chemistry Reviews, 60. pp. 569-585.
Official URL: https://pubs.acs.org/doi/full/10.1021/mc-2025-vol6...
Abstract
no abstract
| Item Type: | Article |
|---|---|
| Date Deposited: | 02 Jan 2026 00:45 |
| Last Modified: | 02 Jan 2026 00:45 |
| URI: | https://oak.novartis.com/id/eprint/57806 |